H.C. Wainwright analyst Oren Livnat dobled the firm’s price target on Agile Therapeutics to $5 from $2.50 and reiterates a Buy rating on the shares. The stock closed Friday down 5% to 69c. Agile’s Twirla, the only low-dose transdermal hormonal contraceptive, should have “tailwinds galvanized by the overturning of Roe,” Livnat tells investors in a research note. The analyst expects acceleration from “significant growth” in new non-retail channels via the company’s Afaxys partnership, its expanded specialty pharmacy network, and the Biden administration enforcing compliance with the Affordable Care Act provisions assuring women straightforward, no-cost access to contraceptives of their and their physician’s choice.
previous post